Australian Testing Finds Wide Potency Gaps in Products Sold as Retatrutide

An Australian laboratory says only one of 18 products sold as retatrutide that it tested during 2026 matched its label claim, adding a broader real-world signal to a recent peer-reviewed analysis of three vials. ABC News published the laboratory’s figures on August 28 Australian time, while it was still August 27 in the United States.

The development matters because retatrutide remains an investigational peptide, not an approved medicine. Products sold online under its name sit outside the manufacturing controls and clinical-trial supply chain used for Eli Lilly’s candidate. The new figures do not establish how representative the tested vials are, but they reinforce a narrower conclusion: a label cannot be assumed to describe the quantity or even the presence of peptide in an unregulated product.

What the testing found

Leeder Analytical told ABC that it had tested 18 black-market samples labelled as retatrutide this year. Only one matched its label claim. About 30% contained more peptide than stated, about 30% contained less, and one contained none. The report did not publish a vial-by-vial table, sampling framework or complete analytical protocol, so those 18 results should be treated as laboratory-reported surveillance rather than a peer-reviewed prevalence estimate.

A research letter published August 6 in *Drug and Alcohol Review* provides fuller methods for three products anonymously submitted to PEDTest Australia. All three were labelled as containing 10 milligrams of retatrutide and were analyzed by an accredited independent laboratory. Molecular-weight analysis detected material consistent with the expected peptide in every vial, but measured content was 5.13, 16.5 and 19.0 milligrams—roughly half, 1.65 times and 1.9 times the labelled amount.

That study also tested for selected metals and inorganic impurities. Lead, copper and zinc were detected at low concentrations, while arsenic, cadmium, chromium, nickel and mercury were below quantitation limits. The authors judged the measured elemental exposures to be below relevant pharmaceutical thresholds. That finding should not be read as a general safety clearance: the investigators did not assess sterility or endotoxin contamination, and three anonymously submitted products cannot characterize an entire illicit market.

Identity is not equivalence

Detecting the expected molecular weight does not show that a vial is equivalent to the investigational product being studied in controlled trials. Peptide medicines can differ in sequence, purity, aggregation, degradation products, formulation and manufacturing residues. Concentration testing also cannot rule out every contaminant.

Australia’s Therapeutic Goods Administration and chief medical officer warned in June that unapproved peptide products, including those sold as retatrutide, have not been evaluated by the regulator for safety, quality or effectiveness. Their joint statement cited reports and hospitalization data involving liver damage, severe allergic reactions and inflammatory complications across unapproved peptide use. It did not establish that every event was caused by retatrutide itself.

ABC’s new report adds clinical concern but not a causal study. It describes physicians treating patients with severe liver injury after use of products labelled as retatrutide. Without complete product characterization and controlled clinical assessment, the relative roles of peptide exposure, contaminants, concentration errors and other factors remain unresolved.

What the evidence can—and cannot—show

The strongest conclusion is about quality uncertainty. The peer-reviewed three-vial analysis directly demonstrated large deviations from labelled content, while the larger laboratory summary suggests that mismatch may extend beyond those samples. Neither dataset estimates the rate of mislabelling across Australia: products were submitted for testing rather than randomly sampled, creating a substantial selection bias.

The findings also do not evaluate retatrutide’s benefits or risks as manufactured by its developer and administered in clinical trials. They evaluate products marketed under the same name through uncontrolled channels.

For clinicians, regulators and researchers, the practical signal is that inaccurate potency deserves attention alongside contamination and outright substitution. More useful surveillance would use prespecified sampling, publish complete analytical methods, test sterility and endotoxins, and connect product chemistry with verified adverse-event investigations. Until then, the evidence supports a focused warning about unreliable contents—not a precise estimate of market-wide risk or a judgment on the investigational drug’s eventual clinical profile.